Aclarion Inc
ACONHealthcare·Health Information Services·USA·Nano·NASD·Nov 12 • 3:59 PM ET
1.59-0.04 (-2.45%)
2026-11-13 13:07 CET
Market cap
$4.58M
Revenue, TTM
0.10 USD m
Net income, TTM
-10.11 USD m
Free cash flow, TTM
-8.96 USD m
EPS diluted, TTM
-5.61
Price
ACON against its 20, 50 and 200-day averagesPatternshover a marker to name it
83.0% under the 52-week high of 9.36 on 8 Jan 2026. 52-week low 1.54 on 11 Nov 2026. Last 15 sessions, 33.8% high to low
Volume 0.00× normal · the session has not printed · the line is the 50-bar volume average
Setup. RS line 0
CANSLIM 2 of 6 — fails: 52-Week High/Low: 0-10% below High; Performance: Year +50%; Institutional Ownership: Over 50%; Average Volume: Over 200K
VCP 3 of 6 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High
Minervini 0 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High; Performance: Year +50%
Zanger 0 of 5 — fails: RSI (14): Not Oversold (>50); Performance: Week +10%; 20-Day High/Low: 0-5% below High; Relative Volume: Over 1.5; 200-Day Simple Moving Average: Price above SMA200
Leaders 0 of 5 — fails: 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%; Average Volume: Over 500K; 52-Week High/Low: 0-10% below High
Breakout 0 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2; 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200
Growth 3 of 4 — fails: Return on Equity: Over +15%
Quality 2 of 5 — fails: Return on Equity: Over +15%; Net Profit Margin: High (>20%) — not on the tape: P/E: Under 25
Value 2 of 4 — fails: Return on Equity: Over +15% — not on the tape: P/E: Under 15
Income 0 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 1 of 4 — fails: Average Volume: Over 500K; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%
Accumulation 0 of 4 — fails: Institutional Ownership: Over 30%; Institutional Transactions: Over +10%; 200-Day Simple Moving Average: Price above SMA200; Performance: Year Up
Relative Strength 0 of 3 — fails: Performance: Year +100%; 200-Day Simple Moving Average: Price above SMA200; Average Volume: Over 500K
Profile
ACON52-week range, 1% of the way up
1.549.36
Aclarion, Inc. is a healthcare technology company, which engages in the provision of Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. It utilizes Artificial Intelligence to assist in quality control processes that flag spectroscopy data indicative of a poor MRS study. It offers NOCISCAN Suite, a revolutionary software suite that works with existing high field Magnetic Resonance systems and Magnetic Resonance Spectroscopy pulse sequence packages using an optimized protocol to conduct MRS exams of lumbar discs. The company was founded by James C. Peacock, David S. Bradford, and Jeffrey Lotz in 2008 and is headquartered in Broomfield, CO.
| Employees | 11 |
|---|---|
| IPO | Apr 22, 2022 |
| Beta | 1.22 |
| ATR, 14d | 0.12 |
| Rel volume | 0.00 |
| Short float | 1.05% |
| Insider own | 29.12% |
| Inst own | 3.96% |
Snapshot
6 groupsValuation
| Index | - |
|---|---|
| Market Cap | $4.58M |
| Enterprise Value | -9.63M |
| Income | -10.11M |
| Sales | 0.10M |
| Book / share | 5.13 |
| Cash / share | 4.93 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | - |
| Employees | 11 |
| IPO | Apr 22, 2022 |
Ratios
| Price / earnings | - |
|---|---|
| Forward price / earnings | - |
| Price / earnings / growth | - |
| Price / sales | 45.80 |
| Price / book | 0.31 |
| Price / cash | 0.32 |
| Price / free cash flow | - |
| Value / cash profit | - |
| Value / sales | -96.30 |
| Quick Ratio | 14.17 |
| Current Ratio | 14.17 |
| Debt / equity | 0.00 |
| Long-term debt / equity | 0.00 |
| Options and short | No / Yes |
Earnings
| Earnings / share | -5.61 |
|---|---|
| Earnings next year | -3.06 |
| Earnings next quarter | -1.15 |
| Earnings this year | 65.27% |
| Earnings next year | 35.44% |
| Earnings growth, 5 years | 50.26% |
| Past earnings growth | 95.75% 83.48% |
| Past sales growth | 7.80% 9.25% |
| Earnings vs last year | 99.65% |
| Sales vs last year | 46.05% |
| Earnings vs last quarter | 67.79% |
| Sales vs last quarter | 78.09% |
| Earnings | Aug 28 |
| Surprise | -6.67% -16.00% |
Ownership
| Insiders own | 29.12% |
|---|---|
| Insider trades | 6.58% |
| Institutions own | 3.96% |
| Institution trades | 0.40% |
| Return on assets | -69.66% |
| Return on equity | -74.07% |
| Return on capital | -68.30% |
| Gross Margin | -222.23% |
| Operating margin | -10789.22% |
| Profit Margin | -10260.05% |
| 20-day average | -12.70% |
| 50-day average | -27.19% |
| 200-day average | -42.37% |
Technical
| Shares out | 2.88M |
|---|---|
| Shares floating | 2.04M |
| Short / float | 1.05% |
| Short ratio | 0.51 |
| Short interest | 0.02M |
| 52-week high | 9.36 -83.0% |
| 52-week low | 1.54 +3.2% |
| Volatility | 6.60% 5.71% |
| Average range | 0.12 |
| Strength index | 33.66 |
| Market sensitivity | 1.22 |
| Relative volume | 0.00 |
| Avg Volume | 42.13K |
| Volume | 0 |
Performance
| Perf Week | 1.92% |
|---|---|
| Perf Month | -18.04% |
| Perf Quarter | -35.37% |
| Perf Half Y | -50.62% |
| Perf YTD | -65.43% |
| Perf Year | -76.94% |
| Perf 3Y | -100.00% |
| Perf 5Y | - |
| Perf 10Y | - |
| Recommendation | 1.00 |
| Target Price | 7.75 |
| Prev Close | 1.59 |
| Price | 1.59 |
| Change % | 0.00% |
Peers
Mkt capInsider trading
11 filings| Insider | Relationship | Date | Transaction | Cost | Shares | Value | Total held | Form |
|---|---|---|---|---|---|---|---|---|
| Williams Amanda M | Director | Aug 17 '26 | Buy | 2.73 | 5,857 | 15,990 | 25,857 | Aug 19 08:30 AM |
| Gould Gregory A | CFO | Aug 14 '26 | Buy | 2.45 | 10,000 | 24,500 | 60,000 | Aug 18 08:30 AM |
| Bond Ryan | Director | Aug 13 '26 | Buy | 2.37 | 21,122 | 50,059 | 76,122 | Aug 17 08:30 AM |
| Wesemann William | Director | Aug 13 '26 | Buy | 2.34 | 2,150 | 5,031 | 23,713 | Aug 17 08:30 AM |
| Neal David K | Director | Aug 13 '26 | Buy | 2.40 | 7,500 | 18,000 | 30,002 | Aug 17 08:30 AM |
| Ness Brent | Chief Executive Officer | Aug 13 '26 | Buy | 2.31 | 5,234 | 12,091 | 111,534 | Aug 17 08:30 AM |
| Breidbart Scott | Director | May 12 '26 | Buy | 3.18 | 5,664 | 18,012 | 5,664 | May 12 06:53 PM |
| Neal David K | Director | May 11 '26 | Buy | 3.10 | 2,500 | 7,750 | 2,502 | May 12 08:30 AM |
| Ness Brent | Chief Executive Officer | May 11 '26 | Buy | 3.18 | 6,289 | 19,999 | 6,300 | May 11 04:30 PM |
| Wesemann William | Director | May 06 '26 | Buy | 3.30 | 1,562 | 5,155 | 1,563 | May 08 05:00 PM |
| Ness Brent | Chief Executive Officer | Nov 26 '25 | Buy | 6.20 | 10 | 62 | 11 | Dec 01 05:00 PM |
Held by
AUM| Ticker | Company | AUM |
|---|---|---|
| VXF | Vanguard Extended Market Index ETF | AUM: 30.79B |
News
latest 14 of 200- Aclarion Announces New Real-World Publication: Nociscan Validated by Strong Agreement with Discography in Diagnosing Painful Lumbar Discs (GlobeNewswire)
- Aclarion Publishes CEO Shareholder Letter Highlighting Continued Scan Volume Growth and Advancing Clinical Program in Third Quarter 2026 (GlobeNewswire)
- Aclarion to Present at the 20th Annual LD Micro Main Event (GlobeNewswire)
- Aclarion Broadens CLARITY Trial Enrollment Criteria to Accelerate Enrollment (GlobeNewswire)
- Aclarion Welcomes NYU Langone Health to CLARITY Trial Network, Now Enrolling at Eleven Sites (GlobeNewswire)
- Aclarion Announces Addition of University of Arizona College of Medicine - Phoenix as CLARITY Trial Site (GlobeNewswire)
- Aclarion Receives Notice of Allowance for Patent Advancing Accuracy and Adoption of Nociscan's MR Spectroscopy (MRS) Scan Process (GlobeNewswire)
- Aclarion Announces Nociscan Now Available at Goodman Campbell Brain & Spine at Ascension St. Vincent, First Site in Indiana to Offer the Technology (GlobeNewswire)
- Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026 (GlobeNewswire) -5.40%
- Aclarion Announces Presentation of Two Abstracts Highlighting Nociscan's Growing Role in Real-World Clinical Practice (GlobeNewswire)
- Aclarion Announces Texas Spine Care Center as New CLARITY Site (GlobeNewswire)
- Aclarion to Present at the Planet MicroCap Las Vegas Powered by MicroCapClub (GlobeNewswire)
- Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform (GlobeNewswire)
- Aclarion Rejects Echo Lake Capital's Unsolicited Acquisition Proposal (GlobeNewswire) -5.88%
Quarterly earnings
2026Q2 EPS -1.120 missed -1.050, from -2.750 a year earlier. Sales 0.03 missed 0.03, from 0.02 a year earlier
The outline behind the bar is the estimate. The filled bar is the print. Green beat it, red missed it.
| Period | Reported | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | Surprise | Year-ago quarter | Analysts | Next session |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026Q2ended 2026-06-30 | 2026-08-28 12:00 | -1.120 | -1.050 | -1.116 | 0.03 | 0.03 | EPS +6.7% · sales -16.0% | vs 2025Q2, year-ago quarter · EPS -59.3% · sales +32.6% | 1 | Open 0.00% vs SPY +0.09%. Close -4.76% vs SPY -0.23% |
| 2026Q1ended 2026-03-31 | 2026-06-03 12:00 | -1.340 | -1.340 | -1.340 | 0.02 | 0.02 | EPS 0.0% · sales 0.0% | vs 2025Q1, year-ago quarter · EPS -85.6% · sales 0.0% | 1 | Open -2.00% vs SPY -0.19%. Close -0.29% vs SPY -0.70% |
| 2025Q4ended 2025-12-31 | 2026-02-25 12:00 | -2.560 | -3.600 | -2.211 | 0.02 | 0.02 | EPS -28.9% · sales -10.0% | vs 2024Q4, year-ago quarter · EPS -99.7% · sales +20.0% | 1 | Open 0.00% vs SPY +0.41%. Close +6.35% vs SPY +0.84% |
| 2025Q3ended 2025-09-30 | 2025-12-03 12:00 | -2.930 | -2.930 | -2.930 | 0.02 | 0.02 | EPS 0.0% · sales 0.0% | vs 2024Q3, year-ago quarter · EPS -99.8% · sales +58.3% | 1 | Open -4.32% vs SPY -0.14%. Close -8.23% vs SPY +0.35% |
| 2025Q2ended 2025-06-30 | 2025-08-22 12:00 | -2.750 | -2.260 | -2.749 | 0.02 | 0.03 | EPS +21.7% · sales -36.7% | vs 2024Q2, year-ago quarter · EPS -99.8% · sales +81.0% | 1 | Open +1.79% vs SPY +0.35%. Close +0.41% vs SPY +1.54% |
| 2025Q1ended 2025-03-31 | 2025-05-28 12:00 | -9.320 | - | -9.318 | 0.02 | - | EPS - · sales - | vs 2024Q1, year-ago quarter · EPS -99.8% · sales +100.0% | - | Open +1.74% vs SPY +0.07%. Close +0.15% vs SPY -0.58% |
| 2024Q4ended 2024-12-31 | 2025-02-26 12:00 | -904.5 | -1,131 | -1,588 | 0.02 | 0.02 | EPS -20.0% · sales -14.3% | - | 2 | Open -0.93% vs SPY +0.28%. Close +2.17% vs SPY +0.05% |
| 2024Q3ended 2024-09-30 | 2024-11-27 12:00 | -1,357 | -1,402 | -1,321 | 0.01 | 0.02 | EPS -3.2% · sales -20.0% | - | 2 | Open +0.72% vs SPY -0.03%. Close -2.21% vs SPY -0.30% |
| 2024Q2ended 2024-06-30 | 2024-08-23 12:00 | -1,357 | -1,357 | -1,363 | 0.01 | 0.01 | EPS 0.0% · sales 0.0% | vs 2023Q2, year-ago quarter · EPS -94.8% · sales -38.6% | 2 | Open +0.48% vs SPY +0.60%. Close +4.85% vs SPY +1.06% |
| 2024Q1ended 2024-03-31 | 2024-05-29 12:00 | -3,980 | -3,980 | -3,987 | 0.01 | 0.01 | EPS 0.0% · sales 0.0% | vs 2023Q1, year-ago quarter · EPS -72.5% · sales -60.0% | 1 | Open -2.99% vs SPY -0.78%. Close -6.71% vs SPY -0.70% |
| 2023Q2ended 2023-06-30 | 2023-08-25 08:30 | -26,050 | -13,025 | -25,575 | 0.02 | 0.05 | EPS +100.0% · sales -65.8% | vs 2022Q2, year-ago quarter · EPS -63.3% · sales +55.5% | 1 | Open +4.30% vs SPY +0.41%. Close -2.20% vs SPY +0.70% |
| 2023Q1ended 2023-03-31 | 2023-05-31 | -14,472 | -14,472 | -21,575 | 0.03 | 0.03 | EPS 0.0% · sales 0.0% | vs 2022Q1, year-ago quarter · EPS -92.6% · sales +177.8% | 1 | Open -15.31% vs SPY -0.45%. Close -6.11% vs SPY -0.55% |
| 2022Q4ended 2022-12-31 | 2023-05-14 | -24,602 | - | -14,579 | 0.02 | - | EPS - · sales - | - | 1 | - |
| 2022Q3ended 2022-09-30 | 2023-01-29 | -30,391 | - | -30,216 | 0.02 | - | EPS - · sales - | - | 1 | - |
| 2022Q2ended 2022-06-30 | 2022-11-05 | -70,913 | - | -70,972 | 0.01 | - | EPS - · sales - | - | 1 | - |
| 2022Q1ended 2022-03-31 | 2022-07-05 | -195,372 | - | -22,637 | 0.01 | - | EPS - · sales - | - | - | - |
Annual earnings
2025FY EPS -13.650 beat -15.130, from -7,492 a year earlier. Sales 0.08 missed 0.08, from 0.00 a year earlier
Reported years only. The outline behind the bar is the estimate. A later year with no print stays in the table.
earnings feed, not the snapshot. Not the statement ratio.
| Period | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | P/E, earnings feed |
|---|---|---|---|---|---|---|
| 2030FYestimate | - | -0.190 | - | - | 18.06 | - |
| 2029FYestimate | - | -0.720 | - | - | 11.66 | - |
| 2028FYestimate | - | -1.680 | - | - | 4.53 | - |
| 2027FYestimate | - | -3.060 | - | - | 0.23 | - |
| 2026FYestimate | - | -4.740 | - | - | 0.11 | - |
| 2025FY | -13.650 | -15.130 | -13.650 | 0.08 | 0.08 | - |
| 2024FY | -7,492 | -7,372 | -7,480 | 0.00 | 0.06 | - |
| 2023FY | -79,777 | - | -79,783 | 0.08 | - | - |
| 2022FY | -189,583 | -189,583 | -177,396 | 0.06 | 0.06 | - |
Quarterly results
2026Q3 revenue 0.03, from 0.02 a year earlier. Operating margin -9,167%, from -9,150% a year earlier
From the quarterly statement. Not an estimate.
Estimate revisions
Latest snapshot of each period and type. 2026FY E -4.74 per share.
| Period | Type | Scale | Date | Mean | vs prior date |
|---|---|---|---|---|---|
| 2026FY | E | per share | 2026-09-30 | -4.74 | +5.1% |
| 2026Q3 | E | per share | 2026-09-30 | -1.15 | +9.5% |
| 2026FY | S | per share | 2026-09-30 | 0.11 | -21.8% |
| 2026Q3 | S | per share | 2026-09-30 | 0.03 | -21.0% |
| 2026Q3 | R | per share | 2026-08-28 | -1.05 | 0.0% |
| 2026Q2 | E | per share | 2026-08-05 | -1.05 | 0.0% |
| 2026FY | R | per share | 2026-08-05 | -4.51 | 0.0% |
| 2026Q2 | R | per share | 2026-08-05 | -1.05 | 0.0% |
| 2026Q2 | S | per share | 2026-06-03 | 0.03 | 0.0% |
| 2026Q1 | E | per share | 2026-05-22 | -1.34 | -13.5% |
| 2026Q1 | R | per share | 2026-05-22 | -1.34 | -13.5% |
| 2026Q1 | S | per share | 2026-05-22 | 0.02 | -20.0% |
| 2025Q4 | E | per share | 2026-02-01 | -3.60 | 0.0% |
| 2025Q4 | R | per share | 2026-02-01 | -3.60 | 0.0% |
| 2025FY | S | per share | 2026-02-01 | 0.08 | 0.0% |
| 2025Q4 | S | per share | 2026-02-01 | 0.02 | 0.0% |
| 2025FY | E | per share | 2025-12-02 | -15.13 | 0.0% |
| 2025FY | R | per share | 2025-12-02 | -15.13 | 0.0% |
| 2025Q3 | E | per share | 2025-11-18 | -2.93 | +11.0% |
| 2025Q3 | R | per share | 2025-11-18 | -2.93 | +11.0% |
| 2025Q3 | S | per share | 2025-11-18 | 0.02 | -5.0% |
| 2025Q2 | E | per share | 2025-06-17 | -2.26 | 0.0% |
| 2025Q2 | R | per share | 2025-06-17 | -2.26 | 0.0% |
| 2025Q2 | S | per share | 2025-05-29 | 0.03 | 0.0% |
| 2025Q1 | E | per share | 2025-03-05 | -16.75 | -52.4% |
| 2025Q1 | R | per share | 2025-03-05 | -16.75 | -52.4% |
| 2025Q1 | S | per share | 2025-03-05 | 0.02 | -20.0% |
| 2024FY | S | per share | 2025-02-25 | 0.06 | 0.0% |
| 2024Q4 | S | per share | 2025-02-25 | 0.02 | 0.0% |
| 2024FY | E | USD millions | 2025-02-25 | -7,372 | 0.0% |
| 2024Q4 | E | USD millions | 2025-02-25 | -1,131 | 0.0% |
| 2024FY | R | USD millions | 2025-02-25 | -7,372 | 0.0% |
| 2024Q4 | R | USD millions | 2025-02-25 | -1,131 | 0.0% |
| 2024Q3 | E | per share | 2024-11-05 | -0.17 | 0.0% |
| 2024Q3 | R | per share | 2024-11-05 | -0.17 | 0.0% |
| 2024Q3 | S | per share | 2024-11-03 | 0.03 | 0.0% |
| 2024Q2 | E | per share | 2024-08-22 | -0.15 | -21.1% |
| 2024Q2 | R | per share | 2024-08-22 | -0.15 | -21.1% |
| 2024Q2 | S | per share | 2024-08-22 | 0.01 | -48.8% |
| 2024Q1 | E | per share | 2024-05-22 | -0.44 | -0.2% |
| 2024Q1 | R | per share | 2024-05-22 | -0.44 | -0.2% |
| 2024Q1 | S | per share | 2024-05-22 | 0.01 | -1.0% |
Estimate history
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | MRQ |
|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -97680.211 | -110583.446 | -120035.11 | -177396.329 | -79782.689 | -7480.215 | -13.609 | -5.6104 | - |
| Sales USD millions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| Shares million shares | 0 | 0 | 0 | 0 | 0 | 0 | 1 | - | 3 |
| Metric | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -1320.932 | -1587.94 | -9.318 | -2.749 | -2.93 | -2.211 | -1.34 | -1.116 | -0.944 |
| Sales USD millions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shares million shares | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 2 | 3 |
Income statement, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.10 | 0.08+60.0% | 0.05-37.5% | 0.08+33.3% | 0.060.0% | 0.06+20.0% | 0.05+66.7% | 0.03 |
| Cost of Goods Sold Incl. D&A | 0.32 | 0.30+7.1% | 0.28+16.7% | 0.24+14.3% | 0.21+5.0% | 0.200.0% | 0.20+11.1% | 0.18 |
| Gross Profit | -0.22 | -0.22 | -0.23 | -0.16 | -0.15 | -0.14 | -0.15 | -0.16 |
| Selling, General and Administrative Excl. Other | 10.41 | 6.83+29.4% | 5.28+12.1% | 4.71-12.9% | 5.41+91.8% | 2.82+21.0% | 2.33-39.6% | 3.86 |
| Research and Development | 1.25 | 1.03+15.7% | 0.89+2.3% | 0.87-18.7% | 1.07+48.6% | 0.72-27.3% | 0.99-41.1% | 1.68 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 2.00 | 0.00 |
| Operating Income | -10.63 | -7.05 | -5.51 | -4.88 | -5.56 | -2.95 | -4.48 | -4.01 |
| Interest Expense | - | - | 0.54-11.5% | 0.61-59.6% | 1.51+214.6% | 0.48+200.0% | 0.16 | 0.00 |
| Unusual Expense | 0.00 | 0.59-37.2% | 0.94 | -0.57 | 0.00 | -0.37 | 0.00 | 0.00 |
| Net Income Before Taxes | -10.11 | -7.23 | -6.99 | -4.91 | -7.07 | -4.95 | -4.64 | -4.02 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -10.11 | -7.23 | -6.99 | -4.91 | -7.07 | -4.95 | -4.64 | -4.02 |
| Net Income From Continuing Operations | -10.11 | -7.23 | -6.99 | -4.91 | -7.07 | -4.95 | -4.64 | -4.02 |
| Net Income | -10.11 | -7.24 | -7.05 | -4.91 | -7.48 | -5.96 | -5.49 | -4.85 |
| EPS (Recurring) per share | -3.64 | -12.84 | -6,778.81 | -86,303.04 | -177,395.63 | -125,304.32 | -110,583.37 | -97,679.65 |
| EPS (Basic, Before Extraordinaries) per share | -5.61 | -13.61 | -7,480.22 | -79,782.69 | -177,396.33 | -120,035.11 | -110,583.45 | -97,680.21 |
| EPS (Diluted) per share | -5.61 | -13.61 | -7,480.22 | -79,782.69 | -177,396.33 | -120,035.11 | -110,583.45 | -97,680.21 |
| EBITDA | -10.39 | -6.82 | -5.32 | -4.71 | -5.42 | -2.76 | -4.28 | -3.84 |
| Non-Operating Income (Expense) | 0.52 | 0.41 | 0.00 | -0.00 | 0.00 | -1.89 | -0.00 | -0.00 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 0.54 | 0.11-62.1% | 0.29-37.0% | 0.46-61.3% | 1.19+561.1% | 0.18+500.0% | 0.030.0% | 0.03 |
| Price To Sales Ratio ratio | 67.94 | 32.32 | 26.86 | 23.63 | 58.59 | - | - | - |
| Gross Margin % | -222.23 | -291.27 | -507.55 | -216.16 | -245.64 | -224.13 | -305.12 | -576.60 |
| Operating Margin % | -10,789.22 | -9,312.55 | -12,057.23 | -6,466.48 | -9,202.51 | -4,899.22 | -9,204.67 | -14,923.98 |
| Net Margin % | -10,260.05 | -9,560.69 | -15,424.29 | -6,513.41 | -12,381.90 | -9,878.40 | -11,277.89 | -18,019.35 |
| Shares Outstanding million shares | 2.88 | 0.85 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Market Capitalization | 4.58 | 4.58+157.3% | 1.78+7.9% | 1.65-63.7% | 4.540.0% | 4.54 | - | - |
Income statement, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.03+50.0% | 0.03+50.0% | 0.020.0% | 0.02+100.0% | 0.02+100.0% | 0.02+100.0% | 0.02+100.0% | 0.010.0% |
| Cost of Goods Sold Incl. D&A | 0.08+14.3% | 0.08+14.3% | 0.080.0% | 0.08+14.3% | 0.070.0% | 0.070.0% | 0.08+33.3% | 0.07+16.7% |
| Gross Profit | -0.05 | -0.05 | -0.06 | -0.06 | -0.05 | -0.05 | -0.06 | -0.06 |
| Selling, General and Administrative Excl. Other | 2.71+52.2% | 2.85+68.6% | 2.93+104.9% | 1.93+10.9% | 1.78+43.5% | 1.69+56.5% | 1.43+17.2% | 1.74+61.1% |
| Research and Development | 0.37+23.3% | 0.30+11.1% | 0.32+60.0% | 0.26+4.0% | 0.30+50.0% | 0.27+35.0% | 0.20-16.7% | 0.25+13.6% |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -2.75 | -2.90 | -2.99 | -1.99 | -1.83 | -1.74 | -1.49 | -1.81 |
| Interest Expense | 0.00 | 0.00 | 0.00 | - | 0.00-100.0% | - | - | 0.00-100.0% |
| Unusual Expense | -0.00 | 0.00 | -0.00-100.0% | 0.00-100.0% | -1E-06 | -0.00 | 0.59-33.0% | 0.09 |
| Net Income Before Taxes | -2.62 | -2.75 | -2.85 | -1.89 | -1.71 | -1.60 | -2.04 | -1.99 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -2.62 | -2.75 | -2.85 | -1.89 | -1.71 | -1.60 | -2.04 | -1.99 |
| Net Income From Continuing Operations | -2.62 | -2.75 | -2.85 | -1.89 | -1.71 | -1.60 | -2.04 | -1.99 |
| Net Income | -2.62 | -2.75 | -2.85 | -1.89 | -1.71 | -1.60 | -2.04 | -2.04 |
| EPS (Recurring) per share | -0.94 | -1.12 | -1.34 | -2.21 | -2.93 | -2.75 | -7.44 | -1,538.82 |
| EPS (Basic, Before Extraordinaries) per share | -0.94 | -1.12 | -1.34 | -2.21 | -2.93 | -2.75 | -9.32 | -1,587.94 |
| EPS (Diluted) per share | -0.94 | -1.12 | -1.34 | -2.21 | -2.93 | -2.75 | -9.32 | -1,587.94 |
| EBITDA | -2.69 | -2.84 | -2.93 | -1.93 | -1.77 | -1.68 | -1.44 | -1.75 |
| Non-Operating Income (Expense) | 0.13+8.3% | 0.15+7.1% | 0.13+225.0% | 0.10 | 0.12 | 0.14 | 0.04-55.6% | -0.09 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 0.42+2000.0% | 0.10+233.3% | 0.00-100.0% | 0.00-100.0% | 0.02-71.4% | 0.03-57.1% | 0.06-33.3% | 0.06-40.0% |
| Price To Sales Ratio ratio | 67.94 | 84.65 | 89.43 | 51.90 | 64.72 | 69.62 | 43.39 | 36.54 |
| Gross Margin % | -144.60 | -212.52 | -270.38 | -322.11 | -284.96 | -245.47 | -314.12 | -611.50 |
| Operating Margin % | -8,164.70 | -11,503.18 | -14,129.33 | -10,785.18 | -9,666.16 | -8,988.60 | -7,855.96 | -17,652.66 |
| Net Margin % | -7,772.91 | -10,899.52 | -13,498.46 | -10,223.18 | -9,007.99 | -8,285.92 | -10,763.62 | -19,909.16 |
| Shares Outstanding million shares | 2.88+396.6% | 2.46+324.1% | 2.44+320.7% | 0.85 | 0.58 | 0.58 | 0.58 | 0.00 |
| Market Capitalization | 4.58+4.8% | 7.09+61.9% | 7.46+36.1% | 3.09+73.6% | 4.37+137.5% | 4.38+113.7% | 5.48+1929.6% | 1.78+7.9% |
Balance sheet, annual
| Metric | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 |
|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 12.04+2517.4% | 0.46-55.3% | 1.03-30.4% | 1.48+228.9% | 0.45+4400.0% | 0.01-92.3% | 0.13 |
| Short Term Receivables | 0.03+50.0% | 0.02+100.0% | 0.01-50.0% | 0.02+100.0% | 0.01-50.0% | 0.02+100.0% | 0.01 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.33+50.0% | 0.22+57.1% | 0.14-30.0% | 0.20-25.9% | 0.27+350.0% | 0.06-25.0% | 0.08 |
| Total Current Assets | 12.40+1671.4% | 0.70-41.2% | 1.19-30.0% | 1.70+132.9% | 0.73+630.0% | 0.10-54.5% | 0.22 |
| Net Property, Plant & Equipment | 0.02+100.0% | 0.01 | 0.00 | 0.00-100.0% | 0.01-66.7% | 0.03-40.0% | 0.05 |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Intangible Assets | 1.25-3.1% | 1.29+10.3% | 1.17-3.3% | 1.21+6.1% | 1.14-2.6% | 1.17+0.9% | 1.16 |
| Deferred Tax Assets | 11.83 | - | - | - | - | - | - |
| Other Assets | 0.00-100.0% | 0.12+20.0% | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Assets | 25.50+1102.8% | 2.12-13.8% | 2.46-15.5% | 2.91+54.0% | 1.89+46.5% | 1.29-9.8% | 1.43 |
| Short Term Debt Incl. Current Port. of LT Debt | 0.00 | 0.00-100.0% | 1.13 | 0.00-100.0% | 2.01-54.1% | 4.38+711.1% | 0.54 |
| Accounts Payable | 0.33-37.7% | 0.53-30.3% | 0.76+65.2% | 0.46-56.6% | 1.06+23.3% | 0.86+72.0% | 0.50 |
| Other Current Liabilities | 0.50-19.4% | 0.62-52.3% | 1.30+465.2% | 0.23-94.9% | 4.55+45.4% | 3.13+49.8% | 2.09 |
| Total Current Liabilities | 0.84-27.0% | 1.15-63.9% | 3.19+362.3% | 0.69-90.9% | 7.62-9.1% | 8.38+167.7% | 3.13 |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax Liabilities | 11.83 | - | - | - | - | - | - |
| Other Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 12.67+1001.7% | 1.15-63.9% | 3.19+362.3% | 0.69-90.9% | 7.62-9.1% | 8.38+167.7% | 3.13 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 12.84+1223.7% | 0.97 | -0.73-132.7% | 2.23 | -5.73 | -7.08 | -1.70 |
| Total Shareholders Equity | 12.84+1223.7% | 0.97 | -0.73-132.7% | 2.23 | -5.73 | -7.08 | -1.70 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 12.84+1223.7% | 0.97 | -0.73-132.7% | 2.23 | -5.73 | -7.08 | -1.70 |
| Total Liabilities & Stockholders Equity | 25.50+1102.8% | 2.12-13.8% | 2.46-15.5% | 2.91+54.0% | 1.89+46.5% | 1.29-9.8% | 1.43 |
| Book Value Per Share per share | 15.02-97.9% | 708.17 | -7,977.03-119.5% | 40,976.92 | -115,473.59 | -142,766.61 | -34,304.58 |
| Tangible Book Value Per Share per share | 13.56 | -236.27 | -20,782.27-211.1% | 18,698.62 | -138,542.35 | -166,326.85 | -57,751.23 |
| Full-Time Employees people | 11+83.3% | 6+50.0% | 4-42.9% | 7+16.7% | 60.0% | 6 | - |
| Price to Book Ratio ratio | 0.31 | 1.84 | -1.99 | 1.55 | 1.55 | - | - |
| Return on Assets % | -52.37 | -305.15 | -182.77 | -294.27 | -311.22 | -340.56 | - |
| Return on Equity % | -104.80 | -5,777.80 | -655.74 | - | - | - | - |
| Return on Invested Capital % | -56.36 | -720.88 | - | -317.55 | - | - | - |
| Quick Ratio ratio | 14.81 | 0.61 | 0.37 | 2.47 | 0.10 | 0.01 | 0.07 |
| Current Ratio ratio | 14.81 | 0.61 | 0.37 | 2.47 | 0.10 | 0.01 | 0.07 |
Cash flow, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -10.11 | -7.23 | -6.99 | -4.91 | -7.07 | -4.95 | -4.64 | -4.02 |
| Depreciation | 0.25 | 0.23+21.1% | 0.19+18.8% | 0.16+14.3% | 0.14-26.3% | 0.19-5.0% | 0.20+11.1% | 0.18 |
| Other Funds (Non Cash) | 0.54 | 0.20-90.4% | 2.09+1206.2% | 0.16-93.8% | 2.59+49.7% | 1.73+1472.7% | 0.11+266.7% | 0.03 |
| Funds from Operations | -9.33 | -6.81 | -4.71 | -4.59 | -4.33 | -3.03 | -4.33 | -3.81 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | 0.38 | -0.36 | -0.56-190.3% | 0.62 | -0.62-191.2% | 0.68+25.9% | 0.54 | -0.36 |
| Cash from Operating Activities | -8.95 | -7.16 | -5.27 | -3.97 | -4.95 | -2.35 | -3.80 | -4.17 |
| Capital Expenditures | -0.21 | -0.20 | -0.32 | -0.12 | -0.21 | -0.15 | -0.18 | -0.27 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | -0.21 | -0.20 | -0.32 | -0.12 | -0.21 | -0.15 | -0.18 | -0.27 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 12.00 | 18.95+255.5% | 5.33+283.5% | 1.39-83.7% | 8.55 | 0.00 | 0.00-100.0% | 2.43 |
| Repurchase of Common Pref Stock | 0.00 | -1.21 | 0.00 | -0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 12.00 | 20.16+278.2% | 5.33+283.5% | 1.39-83.7% | 8.55 | 0.00 | 0.00-100.0% | 2.43 |
| Proceedsfrom Stock Options | -5.00 | -2.41-259.6% | 1.51+8.6% | 1.39 | 0.00 | 0.00 | 0.00-100.0% | 2.43 |
| Issuance or Reduction of Debt, Net | 0.00 | 0.00 | -0.30-113.3% | 2.25 | -2.00-168.0% | 2.94+58.1% | 1.86+257.7% | 0.52 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | -0.37 | 0.00-100.0% | 2.00 | 0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | -0.37 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | 12.00 | 18.95+276.7% | 5.03+38.2% | 3.64-41.2% | 6.19+110.5% | 2.94-23.8% | 3.86+30.8% | 2.95 |
| Net Change in Cash | 2.85 | 11.58 | -0.57 | -0.45-143.7% | 1.03+134.1% | 0.44 | -0.11 | -1.49 |
| Free Cash Flow | -8.96 | -7.19 | -5.28 | -3.97 | -4.95 | -2.35 | -3.80 | -4.19 |
| Preferred Dividends (Cash Flow) | - | - | - | 0.00 | - | - | - | - |
| Deferred Taxes & Investment Tax Credit | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Balance sheet, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 14.21+25.0% | 16.31+26.9% | 19.03+28.9% | 12.04+2517.4% | 11.37+761.4% | 12.85+989.0% | 14.76+589.7% | 0.46-55.3% |
| Short Term Receivables | 0.030.0% | 0.03+50.0% | 0.04+100.0% | 0.03+50.0% | 0.03+50.0% | 0.020.0% | 0.020.0% | 0.02+100.0% |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.33-26.7% | 0.46-9.8% | 0.31-11.4% | 0.33+50.0% | 0.45-2.2% | 0.51-10.5% | 0.35-7.9% | 0.22+57.1% |
| Total Current Assets | 14.58+23.1% | 16.79+25.5% | 19.38+28.1% | 12.40+1671.4% | 11.84+557.8% | 13.38+651.7% | 15.13+495.7% | 0.70-41.2% |
| Net Property, Plant & Equipment | 0.02+100.0% | 0.02+100.0% | 0.02+100.0% | 0.02+100.0% | 0.01 | 0.01 | 0.01 | 0.01 |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Intangible Assets | 1.23-3.9% | 1.22-6.9% | 1.24-6.1% | 1.25-3.1% | 1.28-0.8% | 1.31+5.6% | 1.32+10.9% | 1.29+10.3% |
| Deferred Tax Assets | - | - | - | 11.83 | - | - | - | - |
| Other Assets | 0.00-100.0% | 0.00-100.0% | 0.00-100.0% | 0.00-100.0% | 0.06-33.3% | 0.06-14.3% | 0.03 | 0.12+20.0% |
| Total Assets | 15.83+19.9% | 18.04+22.3% | 20.64+25.2% | 25.50+1102.8% | 13.20+313.8% | 14.75+377.3% | 16.48+341.8% | 2.12-13.8% |
| Short Term Debt Incl. Current Port. of LT Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.00-100.0% | 0.00-100.0% |
| Accounts Payable | 0.24-11.1% | 0.70+150.0% | 0.59+13.5% | 0.33-37.7% | 0.27-18.2% | 0.28+55.6% | 0.52+160.0% | 0.53-30.3% |
| Other Current Liabilities | 0.79+83.7% | 0.33+17.9% | 0.40+122.2% | 0.50-19.4% | 0.43+22.9% | 0.28-42.9% | 0.18-50.0% | 0.62-52.3% |
| Total Current Liabilities | 1.03+47.1% | 1.04+85.7% | 0.99+41.4% | 0.84-27.0% | 0.70+2.9% | 0.56-61.4% | 0.70-42.6% | 1.15-63.9% |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax Liabilities | - | - | - | 11.83 | - | - | - | - |
| Other Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 1.03+47.1% | 1.04+85.7% | 0.99+41.4% | 12.67+1001.7% | 0.70+2.9% | 0.56-61.4% | 0.70-42.6% | 1.15-63.9% |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 14.81+18.5% | 17.00+19.8% | 19.65+24.5% | 12.84+1223.7% | 12.50+398.0% | 14.19+765.2% | 15.78+528.7% | 0.97 |
| Total Shareholders Equity | 14.81+18.5% | 17.00+19.8% | 19.65+24.5% | 12.84+1223.7% | 12.50+398.0% | 14.19+765.2% | 15.78+528.7% | 0.97 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 14.81+18.5% | 17.00+19.8% | 19.65+24.5% | 12.84+1223.7% | 12.50+398.0% | 14.19+765.2% | 15.78+528.7% | 0.97 |
| Total Liabilities & Stockholders Equity | 15.83+19.9% | 18.04+22.3% | 20.64+25.2% | 25.50+1102.8% | 13.20+313.8% | 14.75+377.3% | 16.48+341.8% | 2.12-13.8% |
| Book Value Per Share per share | 5.13-76.1% | 6.91-71.6% | 8.04-70.3% | 15.02-97.9% | 21.46-99.1% | 24.37-98.7% | 27.10-99.1% | 708.17 |
| Tangible Book Value Per Share per share | 4.71-75.5% | 6.41-71.0% | 7.53-69.7% | 13.56 | 19.26-98.2% | 22.12-95.1% | 24.84-98.5% | -236.27 |
| Full-Time Employees people | - | - | - | 11+83.3% | - | - | - | 6+50.0% |
| Price to Book Ratio ratio | 0.31 | 0.36 | 0.22 | 0.21 | 0.31 | 0.28 | 0.00 | 1.84 |
| Return on Assets % | -69.66 | -56.09 | -43.37 | -52.37 | -89.50 | -78.39 | -65.63 | -305.15 |
| Return on Equity % | -74.07 | -58.97 | -45.43 | -104.80 | -97.72 | -88.35 | -72.53 | -5,777.80 |
| Return on Invested Capital % | -17.71 | -16.16 | -14.52 | -14.72 | -13.65 | -11.28 | -12.91 | -205.10 |
| Quick Ratio ratio | 14.17 | 16.20 | 19.65 | 14.81 | 16.93 | 23.71 | 21.64 | 0.61 |
| Current Ratio ratio | 14.17 | 16.20 | 19.65 | 14.81 | 16.93 | 23.71 | 21.64 | 0.61 |
Cash flow, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -2.62 | -2.75 | -2.85 | -1.89 | -1.71 | -1.60 | -2.04 | -1.99 |
| Depreciation | 0.060.0% | 0.06+20.0% | 0.060.0% | 0.06+20.0% | 0.06+20.0% | 0.050.0% | 0.06+20.0% | 0.05+25.0% |
| Other Funds (Non Cash) | 0.42+2000.0% | 0.10+233.3% | 0.00-100.0% | 0.00-100.0% | 0.02-94.7% | 0.03-66.7% | 0.15-87.1% | 0.47+104.3% |
| Funds from Operations | -2.13 | -2.58 | -2.79 | -1.82 | -1.63 | -1.52 | -1.83 | -1.47 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | 0.11-76.6% | -0.07 | 0.15 | 0.20-64.9% | 0.47+291.7% | -0.35 | -0.68 | 0.57+128.0% |
| Cash from Operating Activities | -2.02 | -2.66 | -2.64 | -1.63 | -1.16 | -1.87 | -2.51 | -0.90 |
| Capital Expenditures | -0.07 | -0.04 | -0.05 | -0.04 | -0.04 | -0.04 | -0.08 | -0.06 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | -0.07 | -0.04 | -0.05 | -0.04 | -0.04 | -0.04 | -0.08 | -0.06 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | 0.00 | 0.00 | 0.00 | - | - | - | - | - |
| Change in Capital Stock | -0.01 | -0.02 | 9.68-42.7% | 2.34+2240.0% | -0.28-126.2% | -1E-06-100.0% | 16.89+337.6% | 0.10-92.8% |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.21 | 0.00 |
| Sale of Common Pref Stock | -0.01 | -0.02 | 9.68-46.5% | 2.34+2240.0% | -0.28-126.2% | -1E-06-100.0% | 18.10+368.9% | 0.10-92.8% |
| Proceedsfrom Stock Options | -0.01 | -0.02 | 0.36-88.8% | -5.33 | -0.28-126.2% | -1E-06-100.0% | 3.21+174.4% | -1.03-174.1% |
| Issuance or Reduction of Debt, Net | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.00 | 0.00-100.0% |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | -0.01 | -0.02 | 9.68-42.7% | 2.34+2240.0% | -0.28-126.2% | -1E-06-100.0% | 16.89+374.4% | 0.10-93.9% |
| Net Change in Cash | -2.10 | -2.72 | 6.99-51.1% | 0.67 | -1.48-1157.1% | -1.91 | 14.30+1188.3% | -0.86-200.0% |
| Free Cash Flow | -2.02 | -2.66 | -2.64 | -1.64 | -1.17 | -1.87 | -2.51 | -0.90 |
Revenue breakdown
USD millions, so a column adds up to the income statement. Share is of the latest year in that split. The change is versus the older year shown, not TTM.
| Name | 2024 | 2025 | vs 2024 | 2025 share |
|---|---|---|---|---|
| Services-Medical Laboratories | 0.05 | 0.08 | +65.6% | 100.0% |
| Total | 0.05 | 0.08 | +65.6% | 100.0% |
| Name | 2024 | 2025 | vs 2024 | 2025 share |
|---|---|---|---|---|
| United States | 0.05 | 0.08 | +65.6% | 100.0% |
| Total | 0.05 | 0.08 | +65.6% | 100.0% |
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 1.05% | 0.0M | 2.0M | 46.04K |
| 2026-10-15 | 1.21% | 0.0M | 2.0M | 51.66K |
| 2026-09-30 | 2.40% | 0.0M | 2.0M | 53.70K |
| 2026-09-15 | 3.73% | 0.1M | 2.0M | 60.94K |
| 2026-08-31 | 1.21% | 0.0M | 2.0M | 62.41K |
| 2026-08-14 | 3.04% | 0.1M | 2.0M | 67.14K |
| 2026-07-31 | 1.79% | 0.0M | 1.8M | 67.31K |
| 2026-07-15 | 2.37% | 0.0M | 1.8M | 91.03K |
| 2026-06-30 | 3.03% | 0.1M | 1.8M | 105.57K |
| 2026-06-15 | 7.01% | 0.1M | 1.8M | 95.17K |
| 2026-05-29 | 8.19% | 0.2M | 2.2M | 102.97K |
| 2026-05-15 | 9.02% | 0.2M | 2.2M | 92.60K |
| 2026-04-30 | 19.77% | 0.3M | 1.3M | 105.96K |
| 2026-04-15 | 14.87% | 0.2M | 1.3M | 101.86K |
| 2026-03-31 | 6.24% | 0.1M | 2.3M | 862.07K |
| 2026-03-13 | 6.26% | 0.1M | 2.3M | 874.01K |
| 2026-02-27 | 15.88% | 0.2M | 1.1M | 863.39K |
| 2026-02-13 | 16.22% | 0.2M | 1.1M | 857.14K |
| 2026-01-30 | 16.97% | 0.2M | 1.1M | 838.83K |
| 2026-01-15 | 14.16% | 0.1M | 1.1M | 806.42K |
Option chain
expiry 2026-11-13| Type | Strike | Bid | Ask | Last | IV | Open int | Volume | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|
| No option chain for this symbol. | ||||||||||
Latest SEC filings
30| Filed | Form | Description | Period | Link |
|---|---|---|---|---|
| 2026-11-05 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-09-30 | SEC |
| 2026-08-19 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-17 | SEC |
| 2026-08-18 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-14 | SEC |
| 2026-08-17 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-13 | SEC |
| 2026-08-17 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-13 | SEC |
| 2026-08-17 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-13 | SEC |
| 2026-08-17 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-13 | SEC |
| 2026-08-06 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-06-30 | SEC |
| 2026-07-09 | S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans | SEC | |
| 2026-06-12 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-11 | SEC |
| 2026-06-12 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-11 | SEC |
| 2026-06-12 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-11 | SEC |
| 2026-06-12 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-11 | SEC |
| 2026-06-12 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-11 | SEC |
| 2026-06-12 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-11 | SEC |
| 2026-06-12 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-11 | SEC |
| 2026-06-12 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-11 | SEC |
| 2026-06-12 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-11 | SEC |
| 2026-06-04 | 8-K | Current report | 2026-06-04 | SEC |
| 2026-05-13 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-03-31 | SEC |
| 2026-05-12 | 4 | Statement of changes in beneficial ownership of securities | 2026-05-12 | SEC |
| 2026-05-12 | 4 | Statement of changes in beneficial ownership of securities | 2026-05-11 | SEC |
| 2026-05-11 | 4 | Statement of changes in beneficial ownership of securities | 2026-05-11 | SEC |
| 2026-05-08 | 4 | Statement of changes in beneficial ownership of securities | 2026-05-06 | SEC |
| 2026-04-27 | DEF 14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | 2026-06-04 | SEC |
| 2026-04-22 | 8-K | Current report | 2026-04-21 | SEC |
| 2026-04-03 | PRE 14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | 2026-06-04 | SEC |
| 2026-03-25 | SCHEDULE 13G | SEC | ||
| 2026-03-19 | 8-K | Current report | 2026-03-19 | SEC |
| 2026-03-19 | 8-A12B | SEC |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 0 | 0 |
| 2026-10 | 0 | 0 | 0 | 0 |
| 2026-09 | 0 | 0 | 0 | 0 |
| 2026-08 | 125.67K | 6 | 0 | 0 |
| 2026-07 | 0 | 0 | 0 | 0 |
| 2026-06 | 0 | 0 | 0 | 0 |
| 2026-05 | 50.92K | 4 | 0 | 0 |
| 2026-04 | 0 | 0 | 0 | 0 |
| 2026-03 | 0 | 0 | 0 | 0 |
| 2026-02 | 0 | 0 | 0 | 0 |
| 2026-01 | 0 | 0 | 0 | 0 |
| 2025-12 | 0 | 0 | 0 | 0 |
| 2025-11 | 62 | 1 | 0 | 0 |
Institutional holders
| Manager | % owned |
|---|---|
| CAPTRUST FINANCIAL ADVISORS | 1.39% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.79% |
| VANGUARD FIDUCIARY TRUST CO | 0.65% |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.62% |
| JANE STREET GROUP, LLC | 0.51% |
| XTX Topco Ltd | 0.45% |
| GEODE CAPITAL MANAGEMENT, LLC | 0.42% |
| BANK OF MONTREAL /CAN/ | 0.35% |
| VANGUARD CAPITAL MANAGEMENT LLC | 0.28% |
| OSAIC HOLDINGS, INC. | 0.26% |
Funds
| Fund | % owned |
|---|---|
| Ultra-Small Company Fund | 0.79% |
| Fidelity Extended Market Index Fund | 0.38% |
| VANGUARD EXTENDED MARKET INDEX FUND | 0.28% |
| Fidelity Series Total Market Index Fund | 0.02% |
OakChart. ACON. Cached 15 minutes. Terms
Some panels did not load: ratings.